Regulatory pathway for the approval of biosimilars: 2m48s
Valid short-term endpoints in the clinical development of
biosimilars: 6m23s
Extrapolating the use of biosimilars; potential combination of
biosimilars with other agents: 8m42s
Design of the Phase III HERITAGE study evaluating the
trastuzumab biosimilar MYL-1401O versus trastuzumab for
HER2-positive metastatic breast cancer: 11m1s
Efficacy and safety of trastuzumab biosimilars: 13m43s
Biosimilars currently approved for cancer in the United States:
16m26s
Clinical implications of the HERITAGE trial for patients with
HER2-positive metastatic breast cancer: 18m33s
Activity and use of filgrastim biosimilars in clinical
practice: 19m48s
Emerging data with rituximab biosimilars: 21m59s
Common myths among oncologists regarding biosimilars:
22m59s
Availability of biosimilar agents in the United States and
ongoing monitoring for safety: 24m31s
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.